Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: LOR who wrote (8084)	10/22/2007 7:00:27 PM
From: esxtarus	Read Replies (1) \| Respond to of 8117

NEWSLETTER Pyng Medical CorporationVolume 4, Fiscal 2007, October 2007 The goal of our newsletter is to better inform investors, customers and partners of our strategic business initiatives as we continue to build upon the strengths of our award winning FAST1™ Intraosseous Infusion System and explore new markets and related opportunities. We believe that an open and transparent public company, with strong financials and a compelling value proposition, creates sustainable shareholder value. Based on the positive feedback we have received, we are confident that your interest and involvement helps us build a stronger company. We welcome your feedback; let us know what you think. Please feel free to forward our newsletter to others who may be interested. Financial Results We have just finished a strong fourth quarter. Our full year unaudited results for fiscal 2007 covering the period 1 October 2006 to 30 September 2007 were very strong: revenue for the year was $4.8 million, an increase of 60% over the previous year. Gross margin was $3.3 million, 69% of revenue, despite the drop in the US dollar. We generated approximately $900,000 in EBITDA cash flow and projected net income of $400,000, equivalent to $0.04/share and well ahead of our guidance for this year. Our balance sheet remains strong with working capital of $1.5 million and no debt. We generated quarter-over-quarter revenue growth throughout this year and consistently delivered income in each quarter. We are pleased with our strong financial results and believe that our revenue growth reinforces the strength of our core product: the FAST1™ Intraosseous Infusion System. Please note that these are unaudited results and that full audited results are expected to be available on SEDAR in early December 2007. Market Expansion and Diversification Pyng appointed a new distributor in January 2007 for the Canadian military market. Just six months later, CTOMS successfully closed the Canadian military (DND) with a significant four-figure sale of new business on the FAST1™. We now have four NATO countries utilizing the FAST1™: USA, Canada, the United Kingdom and Poland. We also completed the process to achieve certification with the Mexico Ministry of Health, in partnership with our Mexican affiliate, Medstent. This is the beginning of our expansion into Latin America. In September, we engaged a contract Region Manager to act as our agent in Europe as we develop our European distributors. This engagement follows our approach in the Asian market where the contractor is not on payroll, may be cancelled on thirty days notice, and leverages complimentary product lines to keep travel and retainer costs to a minimum. We are confident that our business on the continent and in the UK will expand under this new arrangement. Product Development and ISO Certification Pyng filed with the FDA for an improvement to our product which will further strengthen our dominant position as the world’s only rapid sternal intraosseous infusion system. We also obtained recertification of both ISO 13485:2003 and ISO 9001:2000 and retained our CE Mark without major non-conformities. This process, which occurs every three years, certifies our ability to meet or exceed the stringent Quality Management System protocols and the regulations required of the medical device industry throughout the world. Pyng Appoints Senior Sales Executive to Lead Revenue Expansion Dave Bonar joined Pyng on September 12th, 2007 as our Vice President Sales and Marketing. Dave has an extremely strong track record in delivering sales growth with established and early stage companies in the hospital, emergency medical services and defense markets, both internationally and domestically, and has hit the ground running. For more information on Dave’s experience, please refer to his bio. In October, Dave was in Orlando, Florida attending EMS Expo, a key emergency medical services tradeshow, with our Director of Education and Marketing Manager, both of whom are also on part-time contracts to keep costs low and variable. David Christie Featured on Business News Network On July 18 David Christie, President and CEO, appeared on the Business News Network and told the Pyng story. Investors took notice. Stock appreciated from its $0.50/share opening to a 52-week high of $0.95/share just hours later, on volumes of almost half-a-million. This exposure and subsequent share activity confirms that Pyng has a great story which is “under-the-radar” and a great value at current prices. David is committed to an initiative this fall to increase our exposure to the financial markets now that we have completed four consecutive quarters of revenue growth and delivered four consecutive quarters of income. The company is well positioned to steadily improve its share price. © Copyright 2007 INVESTORS Newsletters HOME SOLUTIONS PRODUCTS FAQs Technical Documents Accreditation NEWS INVESTORS Newsletters ABOUT US Management Team Board of Directors Testimonials CONTACT US How to Purchase Conferences Careers